Therapeutic Asset Ratings
130 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Eribulin
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P3
B
(60)
Tucatinib
HER2-positive Breast Cancer
MedSIR
P3
B
(60)
FLUOROURACILUM
HER2-positive Breast Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
P3
B
(58)
TAMOXIFEN
HER2-positive Breast Cancer
University of Chicago
P3
B
(58)
Loperamide
HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
P2
B
(58)
Arimidex
HER2-positive Breast Cancer
Sun Yat-sen University
P3
B
(57)
EXEMESTANE
HER2-positive Breast Cancer
Sun Yat-sen University
P3
B
(57)
Neratinib
HER2-positive Breast Cancer
Fudan University
P3
B
(57)
hb1801
HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.
P3
B
(56)
ibi354
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
P3
B
(56)
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated at glutaminyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable linker
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P3
B
(56)
Jskn003
HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.
P3
B
(56)
tqb2102
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P3
B
(56)
Cetuximab
HER2-positive Breast Cancer
Sun Yat-sen University
P2
B
(56)
Irinotecan
HER2-positive Breast Cancer
Sun Yat-sen University
P2
CCC
(55)
Pembrolizumab
HER2-positive Breast Cancer
M.D. Anderson Cancer Center
P2
CCC
(55)
arx788
HER2-positive Breast Cancer
Henan Cancer Hospital
P2/3
CCC
(54)
Fludarabine
HER2-positive Breast Cancer
National University Hospital, Singapore
P1/2
CCC
(54)
bnt323
HER2-positive Breast Cancer
DualityBio Inc.
P3
CCC
(52)
gq1005
HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd.
P3
CCC
(52)
hlx11
HER2-positive Breast Cancer
Shanghai Henlius Biotech
P3
CCC
(52)
SYSA-1901 (pertuzumab biosimilar)
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P3
CCC
(52)
tqb2101 for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
P3
CCC
(52)
Trastuzumab Pamirtecan
HER2-positive Breast Cancer
DualityBio Inc.
P3
CCC
(52)
Fam-Trastuzumab Deruxtecan-Nxki
HER2-positive Breast Cancer
Memorial Sloan Kettering Cancer Center
P2
CCC
(52)
Showing 26 to 50 of 130 assets
Previous
Page 2 of 6
Next
